A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal Cancer

Recruiting

Phase 2

ItraconazoleA Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal Cancer

Sponsor:

VA Office of Research and Development

Code:

NCT05563766

Conditions

Esophageal Adenocarcinoma

Esophageal Squamous Cell Carcinoma

Gastroesophageal Junction Carcinoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Itraconazole

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-04-19. This information was provided to ClinicalTrials.gov by VA Office of Research and Development on 2024-11-21.